Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01606007 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,282
- Enrollment target
NCT01606007 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,282 participants.
The verdict
NCT01606007, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,282 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of this treatment will also be studied.
Interventions
- DRUG Dapagliflozin
- DRUG Saxagliptin
- DRUG Metformin XR
- DRUG Placebo matching with Saxagliptin
- DRUG Placebo matching with Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,282 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01606007
The ClinicalTrials.gov registry entry for NCT01606007 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dapagliflozin is the first listed.
NCT01606007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01606007 about?
NCT01606007 is a clinical study titled "Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes". The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of this treatment will also b...
What is the current status of trial NCT01606007?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,282 participants. The study started on 2012-07. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01606007?
The interventions under investigation include: Dapagliflozin (DRUG), Saxagliptin (DRUG), Metformin XR (DRUG), Placebo matching with Saxagliptin (DRUG), Placebo matching with Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01606007?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.